886 results on '"Ranson, M."'
Search Results
2. Quasi-experimental study designs series–paper 12: strengthening global capacity for evidence synthesis of quasi-experimental health systems research
3. Quality of Hysterectomy Care in Rural Gujarat: The Role of Community-Based Health Insurance
4. 841 Metabolic reprogramming by cancer-associated mutant OXA1L promotes tumor progression and dedifferentiation
5. 842 Extrachromosomal DNA in cutaneous squamous cell carcinoma is associated with increased nodal disease
6. 806 Immune related gene expression analysis of de novo primary skin cancers in patients receiving immune checkpoint inhibitors for advanced cSCC
7. A phase I, dose escalation, pharmacodynamic, pharmacokinetic, and food-effect study of α2 integrin inhibitor E7820 in patients with advanced solid tumors
8. AZD3514, an oral selective androgen receptor down-regulator in patients with castration-resistant prostate cancer – results of two parallel first-in-human phase I studies
9. High-dimensional and spatial analysis reveals immune landscape dependent progression in cutaneous squamous cell carcinoma
10. Phase I pharmacokinetic and pharmacodynamic study of the bioreductive drug RH1
11. Equitable Utilisation of Indian Community Based Health Insurance Scheme among Its Rural Membership: Cluster Randomised Controlled Trial
12. Barriers to accessing benefits in a community-based insurance scheme: lessons learnt from SEWA Insurance, Gujarat
13. CRTs – Cluster Randomized Trials or "Courting Real Troubles": Challenges of Running a CRT in Rural Gujarat, India
14. Proteoglycans in Cellular Recognition and Secretory Functions in the Haemopoietic System
15. Erlotinib in combination with pemetrexed for patients with advanced non-small-cell lung cancer (NSCLC): a phase I dose-finding study
16. Safety, tolerability, pharmacokinetics and pharmacodynamics of the oral cyclin-dependent kinase inhibitor AZD5438 when administered at intermittent and continuous dosing schedules in patients with advanced solid tumours
17. Promoting health equity in conflict-affected fragile states
18. Intervention complexity: a conceptual framework to inform priority-setting in health
19. Global and regional estimates of the effectiveness and cost-effectiveness of price increases and other tobacco control policies
20. Quality of hysterectomy care in rural Gujarat: the role of community-based health insurance
21. Targeting the urokinase plasminogen activator (uPA) pathway inhibits pancreatic cancer progression
22. Optimisation of circulating biomarkers of cell death for routine clinical use
23. Current status and future potential of somatic mutation testing from circulating free DNA in patients with solid tumours
24. A phase I dose-escalation and bioavailability study of oral and intravenous formulations of erlotinib (Tarceva®, OSI-774) in patients with advanced solid tumors of epithelial origin
25. Qualification of M30 and M65 ELISAs as surrogate biomarkers of cell death: long term antigen stability in cancer patient plasma
26. Validation of the comet-X assay as a pharmacodynamic assay for measuring DNA cross-linking produced by the novel anticancer agent RH1 during a phase I clinical trial
27. Protecting the poor? the distributional impact of a bundled insurance scheme
28. Illustrated State-of-the-Art Capsules of the ISTH 2020 Congress
29. Illustrated State-of-the-Art Capsules of the ISTH 2020 Congress
30. Measuring improved targeting of health interventions to the poor in the context of a community-randomised trial in rural India
31. Un bloc nerveux régional permet d'optimiser la technique de création d'un accès artério-veineux pour hémodialyse en améliorant la dilatation veineuse superficielle
32. Making health insurance work for the poor: Learning from the Self-Employed Women's Association's (SEWA) community-based health insurance scheme in India
33. Assessment of diurnal changes and confounding factors that affect circulating cell death biomarker levels: A short communication☆,☆☆
34. In Vitro Cytotoxicity of Bismuth-213 (213bi)-Labeled-Plasminogen Activator Inhibitor Type 2 (Alpha-PAI-2) on Human Breast Cancer Cells
35. Making health insurance work for the poor: Learning from the Self-Employed Women's Association's (SEWA) community-based health insurance scheme in India
36. Estimates of global and regional smoking prevalence in 1995, by age and sex
37. Learning from toxicity patterns in phase I trials during the era of mechanism targeted agents
38. IN VIVO PHARMACOKINETICS OF RADIOIODINATED UROKINASE PLASMINOGEN ACTIVATOR (UPA) INHIBITORS FOR IMAGING METASTATIC CANCER: O30
39. Crystal structure of uPA_H99Y in complex with 50F
40. Crystal structure of uPA_H99Y in complex with 31F
41. Crystal structure of uPA_H99Y in complex with 3-azanyl-5-(azepan-1-yl)-N-carbamimidoyl-6-(furan-2-yl)pyrazine-2-carboxamide
42. Crystal structure of uPA_H99Y in complex with 3-azanyl-5-(azepan-1-yl)-N-[bis(azanyl)methylidene]-6-chloranyl-pyrazine-2-carboxamide
43. Promoting access, financial protection and empowerment for the poor
44. Novel therapies for mesothelioma
45. Human plasminogen and Group A Streptococcal M-like protein: interaction, conformational transition and activation: O9–04
46. Biomarker method validation in anticancer drug development
47. Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer
48. The global burden of trachomatous visual impairment: I. Assessing prevalence
49. The global burden of trachomatous visual impairment: II. assessing burden
50. The public health implications of multilateral trade agreements
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.